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Strengths and limitations of this study
 ► We plan to conduct the first network meta-analy-
sis to assess the relative efficacy and complication 
rates of treatment methods for cervical preinvasive 
and early microinvasive disease.
 ► This study will produce comprehensive summaries 
of the clinical ranking of treatments and will employ 
methodologies that will allow the use of both ran-
domised and observational data, aiming to use all 
published evidence.
 ► The results will inform clinicians, patients and clini-
cal guidelines and will allow effective patient coun-
selling at colposcopy clinics.
 ► We expect to find retrospective observational stud-
ies at high risk of recall, selection and publication 
bias. We will try to overcome this limitation by em-
ploying methods that aim to minimise bias.
ABSTRACT
Introduction Local treatments for cervical intraepithelial 
neoplasia (CIN) and microinvasive disease remove or ablate 
a cone-shaped part of the uterine cervix containing the 
abnormal cells. A trend toward less radical techniques has 
raised concerns that this may adversely impact the rates of 
precancerous and cancerous recurrence. However, there has 
been no strong evidence to support such claims. We hereby 
describe a protocol of a systematic review and network 
meta-analysis that will update the evidence and compare all 
relevant treatments in terms of efficacy and complications.
Methods and analysis Literature searches in electronic 
databases (CENTRAL, MEDLINE, EMBASE) or trial registries 
will identify published and unpublished randomised 
controlled trials (RCTs) and cohort studies comparing the 
efficacy and complications among different excisional and 
ablative techniques. The excisional techniques include cold 
knife, laser or Fischer cone, large loop or needle excision 
of the transformation zone and the ablative radical point 
diathermy, cryotherapy, cold coagulation or laser ablation. 
The primary outcome will be residual/recurrent disease 
defined as abnormal histology or cytology of any grade, while 
secondary outcomes will include treatment failure rates 
defined as high-grade histology or cytology, histologically 
confirmed CIN1+ or histologically confirmed CIN2+, human 
papillomavirus positivity rates, involved margins rates, 
bleeding and cervical stenosis rates. We will assess the 
risk of bias in RCTs and observational studies using tools 
developed by the Cochrane Collaboration. Two authors will 
independently assess study eligibility, abstract the data 
and assess the risk of bias. Random-effects meta-analyses 
and network meta-analyses will be conducted using the 
OR for dichotomous outcomes and the mean difference 
for continuous outcomes. The quality of the evidence for 
the primary outcome will be assessed using the CINeMA 
(Confidence In Network Meta-Analysis) tool.
Ethics and dissemination Ethical approval is not 
required. We will disseminate findings to clinicians, policy-
makers, patients and the public.
PROSPERO registration number CRD42018115508.
InTROduCTIOn
Organised screening programmes in coun-
tries such as the UK have led to a dramatic 
decrease in the incidence and mortality from 
cervical cancer, especially when compared 
with the corresponding statistics for the 
other major cancers. Over a 20-year period, 
from 1993 to 1995 to 2013–2015, the overall 
age-standardised incidence rate of cancer in 
females increased by 16% in the UK,1 whereas 
the corresponding data for cervical cancer 
showed a decrease of 24%.2 Cervical cancer 
is largely preventable through detection 
and treatment of the preinvasive precursor, 
cervical intraepithelial neoplasia (CIN).3 
The local treatment methods are divided 
into excisional and destructive (ablative) 
that aim to remove or ablate, respectively, a 
 o
n
 April 22, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028008 on 2 August 2019. Downloaded from 
2 Athanasiou A, et al. BMJ Open 2019;9:e028008. doi:10.1136/bmjopen-2018-028008
Open access 
cone-shaped part of the cervix that contains the ‘transfor-
mation zone’ with the precancerous cells. Although large 
loop excision of the transformation zone (LLETZ) is the 
most commonly used methods in the UK4 given its ease 
of execution and low cost, the preference of techniques 
varies across Europe and internationally.
A Cochrane systematic review of randomised 
controlled trials (RCTs) concluded that all local treat-
ment techniques are highly effective in preventing 
preinvasive recurrence.5 However, this review found no 
evidence of difference in treatment failure rates among 
the treatment techniques. This could be because the 
RCTs and the subsequent meta-analysis might have 
been underpowered to detect differences between 
the treatments. The largest study recruited only 390 
participants,6 while the majority of the rest were much 
smaller. A larger population-based study from Sweden,7 
which included 150 883 women diagnosed and treated 
for CIN3 (3 148 222 woman-years), reported a doubled 
standardised incidence ratio for post-treatment invasive 
recurrence during the follow-up period of around four 
decades in comparison to the general population, and 
initiated debates on the impact that less radical treat-
ments may have on the subsequent risk of invasion.8 The 
trend toward techniques that remove smaller parts of the 
cervix can be attributed to the fact that many of these are 
easy to do, they are of low cost and can be performed in 
an outpatient setting. Increased awareness of the impact 
of the more radical or deeper techniques on the risk of 
prematurity may have also contributed.9–20
The impact of different techniques on the risk of prein-
vasive and/or invasive recurrence remains therefore 
unclear. With some advocating the minimum radicality 
of treatment to prevent treatment-induced reproduc-
tive morbidity,10 21 and others raising concerns about the 
increase in the risk of future invasion,7 8 a definite answer 
regarding the relative merits and risks among the various 
treatment strategies is required.
Traditionally, treatment strategies are evaluated via 
large, expensive trials. Given the possibly comparable 
(and high) efficacy of most interventions for CIN, it is 
unlikely that any adequately powered RCT assessing the 
relative efficacy of different treatment techniques will 
ever be conducted. Such a trial would require thousands 
of women to reach the statistical power needed to detect 
differences in the preinvasive and invasive recurrence 
rates. In summary, there is currently a lack of adequately 
powered randomised evidence to allow us to compare 
the various interventions. However, there is a plethora of 
available observational studies in the field. These studies 
are a potentially valuable source of evidence and may act 
as a complement to the available randomised evidence, 
allowing us to more accurately assess the comparative 
effectiveness and safety of the various treatment alter-
natives. In this paper, we aim to perform a systematic 
review of both randomised and observational studies in 
the field and quantitatively synthesise their findings in 
meta-analyses.
Systematic reviews and pairwise meta-analyses are 
widely accepted as a useful tool in comparative effec-
tiveness research and are commonly used to summarise, 
critically appraise and synthesise evidence from multiple 
studies. Investigators aiming to address a research ques-
tion identify all relevant studies, evaluate their quality, 
synthesise their findings (meta-analysis) and interpret the 
provided evidence. Systematic reviews and meta-analyses 
have played a key role in providing evidence on the effi-
cacy and safety of treatment methods and management 
strategies in cervical cancer prevention. However, the 
increased number of management strategies and multiple 
treatment options requires the use of more advanced 
evidence-synthesis methods.
Network meta-analysis (NMA) is an extension of pair-
wise meta-analysis, for the case when multiple treatments 
are available for the same condition. NMA has been 
recognised by the National Institute for Health and Care 
Excellence22 and several international health technology 
assessment agencies23 24 as a methodological tool that has 
the potential to increase precision in treatment effect 
estimates but also to infer on the clinical efficacy/safety 
between treatments that have never been compared 
in trials. NMA uses both direct evidence (ie, coming 
from studies comparing head-to-head the treatments of 
interest) and indirect evidence (ie, coming from studies 
comparing the treatments of interest via an intermediate 
common comparator),25–28 allows the estimation of rela-
tive treatment effects between all available interventions 
and provides a clinically useful ranking of the different 
competing treatments. The methodology of NMA has 
never been used before to assess the comparative efficacy 
and complications of different treatment techniques used 
in the management of CIN. Furthermore, novel NMA 
methodologies will be employed to allow the use of both 
randomised and observational data.
The aim of this systematic review and NMA is to 
compare and clinically rank the alternative treatment 
techniques for CIN based on their efficacy, complications 
and adverse effects. This NMA forms part of the CIRCLE 
project (Cervical Cancer Incidence, CIN Recurrence 
and Reproduction after Local Excision), which aims to 
generate a clinically useful ranking of alternative options 
for the treatment of CIN according to their efficacy (risk 
of preinvasive and invasive recurrence), morbidity and 
cost-effectiveness.
METhOdS And AnAlySIS
This protocol is written in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-Anal-
ysis Protocols (see online supplementary file 1).29 
PROSPERO registration will be updated if we make 
any amendments to this protocol. The start date was 
1 October 2018 with expected end date on 1 October 
2020.
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Figure 1 Network of possible pairwise comparisons 
between eligible treatment methods. CC, cold coagulation; 
CKC, cold knife conisation; CT, cryotherapy; FCBE, 
Fischer cone biopsy excision; LA, laser ablation; LC, laser 
conisation; LEEP, loop electrosurgical excisional procedure; 
LLETZ, large loop excision of the transformation zone; 
NETZ, needle excision of the transformation; RD, radical 
point diathermy; SWETZ, straight-wire excision of the 
transformation zone.
Eligibility criteria of studies
Types of participants
We will include women of all ages treated with local 
surgical treatment for CIN (or glandular intraepithelial 
neoplasia) or microinvasive early cervical cancer (stage 
1a1). We will only include women with histological diag-
nosis of CIN on punch biopsy or cone.
Types of interventions
The treatment techniques for CIN are divided into exci-
sional and ablative. The excisional include cold knife 
conisation, laser conisation, needle excision of the trans-
formation zone, also known as straight-wire excision of 
the transformation zone, LLETZ, also known as loop 
electrosurgical excisional procedure and Fischer cone 
biopsy excisor, while the ablative include radical point 
diathermy, cryotherapy, cold coagulation and laser abla-
tion. Figure 1 displays a network example of comparisons 
between studied treatment techniques.
Outcome measures
Primary outcome
 ► Treatment failure rates defined as any abnormal 
cytology (atypical squamous cells of undetermined 
significance or worse) or histology (CIN1 or worse).
Secondary outcomes
 ► Treatment failure rates defined as high-grade 
abnormal cytology (high-grade squamous intraepi-
thelial lesion or worse) or histology (CIN2 or worse).
 ► Treatment failure rates defined as residual or recur-
rent histologically proven CIN1 or worse.
 ► Treatment failure rates defined as residual or recur-
rent histologically proven CIN2 or worse.
 ► Human papillomavirus (HPV) positivity rates.
 ► Involved margins rates (incomplete excision of 
the lesion): both endocervical and ectocervical 
involvement.
 ► Perioperative or postoperative bleeding.
 ► Cervical stenosis.
Primary and secondary outcomes were chosen by clin-
ical experts of the team. Treatment failure rates and HPV 
positivity rates will be reported at intervals of 6 to 12 
months based on the available data and reported inter-
vals in the included studies.
Types of studies
We will include RCTs, quasi-RCTs and observational 
cohort studies comparing rates of treatment failure 
(recurrent/residual disease) or complications among the 
abovementioned surgical techniques. Single-arm studies 
not presenting a comparison will be excluded. Studies 
will be considered regardless of time or language.
Information sources and search strategy
The Cochrane Gynaecological Cancer Specialised 
Register, Cochrane Central Register of Controlled Trials 
(CENTRAL), MEDLINE and EMBASE will be searched 
for eligible studies by an experienced librarian, as 
presented in online supplementary file 2. Metaregister, 
Physicians Data Query, www. controlled- trials. com/ rct, 
www. clinicaltrials. gov, www. cancer. gov/ clinicaltrials and 
WHO Registry Network (https://www. who. int/ ictrp/ 
network/ en/) will be searched for ongoing studies. 
ZETOC (http:// zetoc. mimas. ac. uk) and WorldCat 
Dissertations will be searched for conference proceed-
ings and theses, respectively. References of the retrieved 
articles and meta-analyses will be hand-searched, the 
‘related articles’ feature in MEDLINE will be employed 
and experts in the field will be contacted in an attempt 
to identify further reports of studies. Corresponding 
authors will be contacted for any relevant ongoing trials 
and unpublished data.
We will include both published and unpublished data 
and there will be no time, place or language restriction; 
articles in language other than English will be translated 
using online translation services.
Study selection
Two team members will independently screen titles 
and abstracts of citations at level 1, using the reference 
management software Zotero. At level 2, the full text of all 
potentially eligible articles will be assessed using the same 
inclusion criteria. Disagreements will be resolved through 
discussion with a third review author.
data collection
Data from the included studies will be abstracted at level 
3 by two reviewers independently using an a priori devel-
oped data collection form in Excel. The following data 
will be abstracted from the included studies: study char-
acteristics, including author, publication year, country, 
study design, inclusion/exclusion criteria and inter-
vention details; participant characteristics, including 
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age, CIN grade and smoking, and dropout rates; and 
outcome characteristics. In RCTs, we will prefer arm-level 
data (number of events and sample size per interven-
tion arm for dichotomous data, and mean and SD per 
intervention arm for continuous data), but if these are 
missing, the study-level data will be used in the analysis, 
for example, reported ORs for dichotomous outcomes 
and mean differences (MDs) for continuous outcomes, 
along with a measure of uncertainly (eg, CI). For contin-
uous outcome data not reported as means and SD, we will 
first contact the corresponding study authors for further 
information, but if no additional data are provided, we 
will perform imputation methods to derive approximate 
effect measures.30 31 When an eligible study is observa-
tional, we will prefer adjusted treatment effect estimates 
accounting for the impact of potential confounders, but 
if these are missing, the unadjusted estimated treatment 
effects will be abstracted with a corresponding uncer-
tainty measure (eg, CI). Disagreements will be resolved 
through consensus or the involvement of a third reviewer.
Risk of bias assessment
RCTs will be assessed for quality and risk of bias using 
the Cochrane risk of bias tool32 in the following domains: 
randomisation process, deviations from the intended 
interventions, missing outcome data, measurement of the 
outcome and selection of the reported result. The risk 
of bias in each domain, as well as the overall risk of bias, 
will be rated as ‘low risk’, ‘some concerns’ or ‘high risk’ 
after answering the signalling questions of each domain 
with ‘Yes’, ‘Potentially Yes’, ‘Potentially No’ or ‘No’. 
Non-randomised studies (NRS) will be assessed using 
the ROBINS-I (Risk Of Bias In Non-Randomised Studies 
of Interventions) tool33 with potential confounding 
factors: grade of treated CIN, age and smoking. The 
following domains will be assessed for NRS: confounding, 
selection of participants into the study, classification of 
interventions, deviations from intended interventions, 
missing data, measurement of outcomes and selection 
of the reported results. The risk of bias in each domain, 
as well as the overall risk of bias, will be rated as ‘low’, 
‘moderate’, ‘serious’ or ‘critical’, after answering the 
signalling questions of each domain with ‘Yes’, ‘Poten-
tially Yes’, ‘Potentially No’ or ‘No’. Pairs of team members 
will independently assess the methodological quality and 
risk of bias of the eligible studies. Conflicts will be resolved 
through discussion or with a third investigator. When 
inadequate information is available from the studies to 
rate a risk of bias item, we will contact the corresponding 
study authors for clarification.
Statistical synthesis
Characteristics of included studies and network
For each outcome, we will produce a network plot (see, 
eg, figure 1) of the available evidence, as well as descrip-
tive statistics, including comparison type, publication 
year, study design, outcome data and potential effect 
modifiers (eg, age).
Pairwise meta-analyses
A random-effects meta-analysis will be conducted for each 
pairwise comparison in each outcome using the inverse 
variance model and the Hartung-Knapp-Sidik-Jonkman 
method to estimate each summary treatment effect and its 
95% CI34–36. The between-study variance will be estimated 
with the restricted maximum likelihood estimator, whereas 
its 95% CI with the Q-profile approach.34 37 38 We will also use 
the I2 statistic along a 95% CI39 40 to evaluate between-study 
heterogeneity. For continuous outcomes we will report the 
summary MDs, whereas for dichotomous outcomes we will 
use the summary ORs, along with a 95% CI. The metafor 
package41 in R42 will be used for all meta-analyses.
Network meta-analyses
Data synthesis
A random-effects NMA will be conducted, since we antic-
ipate methodological and clinical between-study hetero-
geneity. We will assume common between-study variance 
parameter across treatment comparisons in the network, 
so that comparisons informed by a single study can borrow 
strength from the remaining network.43 44 This assumption 
is clinically reasonable because all treatments included in 
the network of trials are of the same nature. The between-
study variance will be estimated with the DerSimonian and 
Laird method of moments approach.45 We will employ NMA 
models that account for different propensity of bias across 
different study designs as described in Efthimiou et al.46 We 
will explore the impact of assigning different levels of cred-
ibility and subsequently downweight the NRS according to 
experts’ opinion and the results of the ROBINS-I tool in 
several sensitivity analyses.
Similar to the pairwise meta-analysis, for continuous 
outcomes we will report the estimated MDs, whereas for 
dichotomous outcomes we will use the estimated ORs, with 
a 95% CI. Along the 95% CI for the summary effect size, 
we will report 95% prediction intervals, that is, the inter-
vals within which the true underlying treatment effect is 
expected to lie in a new trial.47 To rank the efficacy for each 
intervention, we will calculate the ranking probabilities for 
all treatments, the surface under the cumulative ranking 
curve (SUCRA) or P-scores and the mean ranks.48 49 A rank-
heat plot will be used to depict the SUCRA values or P-scores 
across all outcomes.50 We will apply all NMA models in R42 
using the netmeta package51 and rjags52 package.
Assessment of the transitivity assumption
One of the prerequisite assumptions in NMA is the tran-
sitivity assumption, under which the effect modifiers have 
a similar distribution across treatment comparisons in a 
network.27 53 54 For the participants’ characteristics that are 
described in the inclusion criteria of our systematic review 
(section type of participants), it is reasonable to assume that 
all treatments we plan to compare (section type of inter-
ventions) are ‘jointly randomisable’. That means that any 
patient that fulfils that inclusion criteria could potentially 
be assigned to any of the interventions. Potential effect 
modifiers expected to influence the estimated treatment 
 o
n
 April 22, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028008 on 2 August 2019. Downloaded from 
5Athanasiou A, et al. BMJ Open 2019;9:e028008. doi:10.1136/bmjopen-2018-028008
Open access
effects include year of study, level of income of study 
country (as defined by World Bank55), method of ascertain-
ment of exposure/outcome (hospital records, registries 
or interviews/questionnaires), age, smoking and grade of 
CIN. For each pairwise comparison with available direct 
evidence, we will summarise these characteristics and will 
visually inspect the similarity of the identified studies. We 
will also investigate the inclusion and exclusion criteria 
of all studies, to make sure that patients, treatments and 
outcomes in the studies are sufficiently similar in all aspects 
that might modify relative treatment effects. More specif-
ically, we will compare the patient characteristics (such as 
severity, age, parity, etc) across the different treatments. If 
these characteristics are found to have a similar distribution 
across treatments, then transitivity is supported. If differ-
ences are found, then these will be addressed in subgroup 
and sensitivity analyses.
Assessment of statistical inconsistency
Consistency in a network of trials will be evaluated both 
locally and globally. We will first assess the consistency 
assumption locally by separating the direct from the indi-
rect evidence for every comparison in a network to make 
judgements about their statistical differences, using the 
back-calculation method.56 Then we will assess consis-
tency in each network globally using the design-by-treat-
ment interaction model.57 We will conceptually explore 
for potential intransitivity in every network even in the 
absence of evidence for inconsistency, since the incon-
sistency tests have low power to detect true inconsis-
tency.58 59 If no substantial inconsistency is identified in 
the network of RCTs, we will then evaluate the agreement 
between RCTs and NRS using the same local and global 
approaches. Both local (back-calculation method) and 
global (design-by-treatment interaction model) assess-
ments will be performed under the random-effects model 
in R42 using the netmeta package.51
In the NMA including both RCTs and NRS, we will assess 
for differences between the different study designs.46 For 
each treatment comparison we will summarise evidence 
by up to four different types: direct randomised, indirect 
randomised, direct non-randomised and indirect non-ran-
domised. If important discrepancies between these types 
are found, these will be investigated to confirm that the 
transitivity assumption holds (eg, when randomised and 
non-randomised evidence are very different in terms of 
populations, interventions, and so on, the transitivity 
assumption may be violated). If disagreement occurs for 
a certain characteristic, this will be explored through a 
network meta-regression model.26
Exploring heterogeneity and inconsistency: subgroup analyses and 
meta-regression
The between-study heterogeneity will be explored by 
comparing the estimated between-study variance with 
the empirical distribution derived by Rhodes et al for 
continuous data60 and the one derived by Turner et al for 
dichotomous data.61 We will also compare 95% CIs with 
the 95% prediction intervals to infer on the magnitude of 
the between-study variance.
If at least 10 studies are available, the following poten-
tial sources of heterogeneity and/or inconsistency will 
be explored for the primary outcome using subgroup or 
metaregression analyses: year of study, level of income of 
study country (as defined by World Bank,55 method of 
ascertainment of exposure/outcome (hospital records, 
registries or interviews/questionnaires), age, smoking, 
grade of CIN and disease severity (eg, women treated for 
high-grade CIN, exclusion of cases of microinvasion). To 
minimise potential bias due to confounding from NRS 
(eg, type of treatment or outcome affected by severity), 
we will also perform a sensitivity analysis excluding NRS 
without adjusted effect estimates.
Reporting bias and small study effects
We will assess small-study effects by visually exploring the 
funnel plot for each treatment, and the comparison-ad-
justed funnel plot62 when at least 10 studies are available. 
We will also conduct a network meta-regression using the 
study variance as a covariate.63 64
Assessment of the credibility of the evidence
For the primary outcome, two team members will deter-
mine the degree of confidence in the estimated NMA 
results using CINeMA (Confidence In Network Meta-Anal-
ysis)65 and the relevant online tool (http:// cinema. ispm. 
ch/). The six CINeMA domains, within-study bias (ie, 
risk of bias in the included studies), across-study bias (ie, 
publication and reporting bias), indirectness, imprecision, 
heterogeneity and incoherence (ie, differences between 
direct and indirect evidence),65 will first be rated as high 
quality and then they will be downgraded if judged appro-
priate to moderate, low or very low quality.
PATIEnT And PuBlIC InvOlvEMEnT
Patients and the wider public have been involved from 
the design of this proposal through clinics and the Jo’s 
Cervical Cancer Trust. They have assisted study design 
and to formulate the research questions. Their involve-
ment will continue throughout the study on regular 6 
monthly meetings and will guide the priority questions to 
be addressed, the development of research reports in lay 
language and the dissemination of the results.
EThICS And dISSEMInATIOn
We do not require ethical approval for this review. We 
aim to disseminate the results to clinicians, academic 
researchers, health agencies, decision-makers, patients 
and the public. We will publish the results in high 
impact open access journals and disseminate findings 
through presentations at medical conferences. The 
data will become available in public repositories. We will 
develop information sheets and briefings, highlighting 
the key findings and circulate newsletters. We will work 
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closed with the Jo’s Trust, charity in cervical cancer that 
frequently organises events to educate the public and also 
engage the media with interviews. We circulate findings 
in the Imperial College London web page and will circu-
late newsletters.
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